BioNTech SENew data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.
Tag Archive for: CTLA-4
AstraZeneca plcAstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products.